Business Wire20d
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
LB432 Improved plasma signature of contraction-induced muscle injury with sevasemten in Becker muscular dystrophy in the CANYON Phase II trial A companion poster presentation will be available for ...
The American Journal of Managed Care12d
EMBARK Data Show Continued Improvements With DMD Gene Therapy
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...